Synergy between contract development and analysis (CDAO) expertise and GMP manufacturing capabilities
[by Sung, Jae Jun] Protium Science, a company specializing in contract development and analysis (CDAO) for biopharmaceuticals, announced on April 9 that it has signed a one-stop Contract Development Analysis, and Manufacturing Organization (CDAMO) agreement with Korea BMI for the development and production of biopharmaceuticals.
This agreement marks the first case of strategic business collaboration between the two companies following their partnership established in 2024. Through this contract, 바카라 카지노 Science and Korea BMI anticipate delivering efficient, integrated (one-stop) CDAMO services while creating synergy in the areas of contract development and consignment manufacturing.
In particular, this 바카라 카지노 is part of an investment-linked program designed as a cooperative model between the two companies. By efficiently utilizing each company’s respective resources, the partnership is expected to further strengthen biopharmaceutical development and manufacturing capabilities while providing more reliable and comprehensive services to clients.
바카라 카지노 Science offers a range of process development services, including cell culture, purification, analysis testing, and production of toxicology study material for clients’ novel drug candidates. Korea BMI will be responsible for providing GMP-compliant manufacturing services for clinical trial materials.
바카라 카지노 Science, a subsidiary of Tium Bio, is a company focused on the development of treatments for rare and intractable diseases and a leading provider of end-to-end biopharmaceutical development services in Korea. Its offerings span from cell line development to the production of raw materials and finished pharmaceutical products. Additionally, the company provides comprehensive consulting services, including the preparation of clinical trial application (CTA) documentation and responses to supplementary requests from regulatory authorities.
Recently, the company has expanded its contract development capabilities to encompass a diverse range of modalities, including antibody-drug conjugate (ADC) sample production, analytical services, and lyophilized formulation development, as well as glucagon-like peptide 1 (GLP-1)-based peptide analysis and lipid nanoparticle (LNP) manufacturing. Since its establishment in 2021, 바카라 카지노 Science has experienced rapid growth, having signed over 500 CDAO contracts and accumulated more than KRW 20 billion (approximately USD 13.7 million) in total orders.